Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Ensovibep  COVID-19 treatment studies for Ensovibep  C19 studies: Ensovibep  Ensovibep   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Mortality 17% Improvement Relative Risk Recovery 6% Recovery, day 5 -8% Discharge 7% c19early.com/ev Barkauskas et al. NCT04501978 ACTIV-3/TICO Ensovibep RCT LATE Favors ensovibep Favors control
Barkauskas, 485 patient ensovibep late treatment RCT: 17% lower mortality [p=0.46], 6% improved recovery [p=0.55], and 7% higher hospital discharge [p=0.46] https://c19p.org/barkauskas
copied to clipboard
Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19
Barkauskas et al., Annals of Internal Medicine, doi:10.7326/M22-1503, ACTIV-3/TICO, NCT04501978 (history)
9 Aug 2022    Source   PDF   Share   Tweet
RCT 485 hospitalized patients showing no significant differences with ensovibep treatment. Intravenous ensovibep, 600mg.
risk of death, 17.0% lower, HR 0.83, p = 0.46, treatment 30 of 247 (12.1%), control 35 of 238 (14.7%), NNT 39, Kaplan–Meier, day 90.
risk of no recovery, 5.7% lower, HR 0.94, p = 0.55, treatment 44 of 247 (17.8%), control 48 of 238 (20.2%), NNT 42, adjusted per study, inverted to make RR<1 favor treatment.
risk of no recovery, 7.5% higher, HR 1.08, p = 0.68, treatment 247, control 238, adjusted per study, inverted to make RR<1 favor treatment, pulmonary ordinal outcome, day 5.
risk of no hospital discharge, 6.5% lower, HR 0.93, p = 0.46, treatment 28 of 247 (11.3%), control 34 of 238 (14.3%), adjusted per study, inverted to make RR<1 favor treatment.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Barkauskas et al., 9 Aug 2022, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, peer-reviewed, 80 authors, average treatment delay 8.0 days, trial NCT04501978 (history) (ACTIV-3/TICO).
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperEnsovibepAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit